The new European Directive laying down basic safety standards for protection against the dangers arising from ionising radiation exposure will come into effect on 6 February 2018. The most relevant change for interventionists in the occupational exposure section is the new annual limit for the lens of the eyes (20 mSv/year, instead of 150 mSv/year), write Eliseo Vano (Madrid, Spain) and Gabriel Bartal (Kfar Saba, Israel).
Janssen Pharmaceuticals has announced that the FDA has approved the 10mg once-daily dose of rivaroxaban (Xarelto) for reducing the continued risk for recurrent venous thromboembolism (VTE) after completing at least six months of initial anticoagulation therapy.
Philips has announced the results of a comprehensive, independent, two-year study demonstrating the clinical workflow benefits of its next generation image-guided therapy platform, Azurion.
The Society of Interventional Radiology (SIR), in coordination with Member of the US House of Representatives (Rep.) from Utah’s 4th district, Mia Love, hosted a panel discussion on the important role of interventional radiologists on trauma teams responding to mass casualty incidents.
Intact Vascular has announced that positive single centre twenty-four month results from its TOBA (Tack optimised balloon angioplasty) clinical study were presented at VEITHsymposium 2017 by Christian Wissgott, assistant director, Westküstenklinikum Heide in Heide, Germany.
Paolo Zamboni, Ferrara, Italy, the proponent of the chronic cerebrospinal venous insufficiency (CCSVI) theory, and his colleagues have reported that the randomised, double-blinded, sham controlled Brave Dreams trial has not demonstrated a benefit for venous angioplasty in the treatment of patients with multiple sclerosis (MS).
The Global Medtech industry is moving together to enhance compliance practices across Europe, China, the Middle East, North Africa and Asia-Pacific, announces a statement released by AdvaMed, APACMed, Mecomed, and MedTech Europe.
XableCath has announced its XableCath blunt tip support catheter has received clearance from the US FDA. The blunt tip catheter facilitates true lumen passage of lesions, both above and below the knee, in the peripheral vasculature.
PQ Bypass has received conditional approval of its investigational device exemption (IDE) from the US Food and Drug Administration (FDA) to initiate the pivotal DETOUR II clinical trial. As the first-ever pivotal trial for percutaneous femoropopliteal bypass, DETOUR II will evaluate the safety and effectiveness of the DETOUR System in up to 292 patients with lower limb ischaemia due to long blockages (>15cm) in the superficial femoral artery (SFA) caused by peripheral artery disease (PAD).
Royal Philips has announced that it has acquired VitalHealth, a provider of cloud-based population health management solutions for the delivery of personalised care outside of the hospital, for example, in regional care networks.
A study of nearly 62,000 hospitalisations nationwide in the USA has found that more than one in six patients with peripheral arterial disease (PAD) who undergo revascularisation procedures to restore blood flow to blocked leg arteries and other arteries outside of the heart are readmitted to the hospital within 30 days.
W L Gore and Associates has announced the first implant of the Gore Excluder conformable abdominal aortic aneurysm endoprosthesis in the USA. The procedure took place on 19 December 2017 at Maimonides Medical Center in New York by Robert Rhee, chief of Vascular and Endovascular Surgery, and national principal investigator.
A new study suggests thoracic endovascular aortic repair (TEVAR) may be appropriate in uncomplicated Type B aortic dissection (TBAD) based on several anatomic criteria determined by CT imaging.
The registry will combine noninvasive, vascular ultrasound testing data with vascular treatment and outcomes data, making it possible to analyse the relationships between diagnosis and care provided to patients with vascular disease.
Enrolment is complete in the Lutonix below-the-knee trial with BD planning to submit a pre-market approval application to the US Food and Drug Administration (FDA) in late 2018.